The Effect of Antihypertensive Medication Timing on Morbidity and Mortality

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 3357 participants.

Also called NCT02990663

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; single masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 3,357 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT02990663
Other papers using this trial's data
  • Antihypertensive Medication Timing and Cardiovascular Events and Death: The BedMed Randomized Clinical Trial JAMA, 2025-06-17 DOI, PubMed 40354045, PMC12070279 Not in the PMC Open Access subset.

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Canada (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02990663. Randomized; single masking; primary purpose treatment. Start 2017-03-31 (actual); primary completion 2023-12-22 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
The Effect of Antihypertensive Medication Timing on Morbidity and Mortality
Condition
Hypertension
Intervention (Other)
Use of blood pressure lowering medication at bedtime
Intervention (Other)
Use of blood pressure lowering medication in the morning
Lead sponsor
University of Alberta (class: other)
Collaborator
Alberta Innovates Health Solutions (class: other)
Collaborator
Alberta Health services (class: other)
Collaborator
Canadian Institutes of Health Research (CIHR) (class: other government)

Record details

Record id
cardio:ct-nct02990663
Content hash
46419de5ddd0f29b5b390ae0da82c264e96631e90d3f49818484d63a94ce03b8